Replies to post #2742 on Seelos Therapeutics Inc (SEEL)

[leoncio1]

so we get more details comming days..

looks good.. hope pp will rise

[califax]

...will jointly present data at the 101st Annual Meeting of the American Association for Cancer Research (AACR), in Washington, D.C. from April 17-21, 2010. The poster presentation, entitled, “Å6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines in in vitro and in vivo studies,” covers pre-clinical work completed by Bio-Quant on Ångstrom’s lead product, Å6, currently in Phase 2 development for ovarian cancer.

NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR
Tuesday April 13, 2010, 11:00 am EDT
http://finance.yahoo.com/news/NexMed-and-ngstrom-bw-3991454208.html?x=0&.v=1